JIDEYTRO (Zidesamtinib) Patent Expiration, LOE Window & CMS Spending

JIDEYTRO (Zidesamtinib) by Nuvalent: FDA Orange Book core substance LOE 2042-09-30, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $33,708 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNuvalent
FDA Application & PathwayN220185 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2042-09-30
Last Listed Patent or Exclusivity Date2042-09-30
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($33,708 intro WAC)